Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,068

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

Open access
Götestam Skorpen, Carina, Hoeltzenbein, Maria, Tincani, Angela, Fischer-Betz, Rebecca, Elefant, Elisabeth, Chambers, Christina, da Silva, Josè, Nelson-Piercy, Catherine, Cetin, Irene, Costedoat-Chalumeau, Nathalie, Dolhain, Radboud, Förger, Frauke, Khamashta, Munther, Ruiz-Irastorza, Guillermo, Zink, Angela, Vencovsky, Jiri, Cutolo, Maurizio, Caeyers, Nele, Zumbühl, Claudia, Østensen, Monika·2016·Annals of the Rheumatic Diseases

Abstract

A European League Against Rheumatism (EULAR) task force was established to define points to consider on use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Based on a systematic literature review and pregnancy exposure data from several registries, statements on the compatibility of antirheumatic drugs during pregnancy and lactation were developed. The level of agreement among experts in regard to statements and propositions of use in clinical practice was established by Delphi voting. The task force defined 4 overarching principles and 11 points to consider for use of antirheumatic drugs during pregnancy and lactation. Compatibility with pregnancy and lactation was found for antimalarials, sulfasalazine, azathioprine, ciclosporin, tacrolimus, colchicine, intravenous immunoglobulin and glucocorticoids. Methotrexate, mycophenolate mofetil and cyclophosphamide require discontinuation before conception due to proven teratogenicity. Insufficient documentation in regard to fetal safety implies the discontinuation of leflunomide, tofacitinib as well as abatacept, rituximab, belimumab, tocilizumab, ustekinumab and anakinra before a planned pregnancy. Among biologics tumour necrosis factor inhibitors are best studied and appear reasonably safe with first and second trimester use. Restrictions in use apply for the few proven teratogenic drugs and the large proportion of medications for which insufficient safety data for the fetus/child are available. Effective drug treatment of active inflammatory rheumatic disease is possible with reasonable safety for the fetus/child during pregnancy and lactation. The dissemination of the data to health professionals and patients as well as their implementation into clinical practice may help to improve the management of pregnant and lactating patients with rheumatic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-208840

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 1,068

Metadata

Authors
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., Nelson-Piercy, C., Cetin, I., Costedoat-Chalumeau, N., Dolhain, R., Förger, F., Khamashta, M., Ruiz-Irastorza, G., Zink, A., Vencovsky, J., Cutolo, M., Caeyers, N., Zumbühl, C., & Østensen, M.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-05
Volume
75
Issue
5
Pages
795-810
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2319070923
Cited by
1,068
References
56
FWCI
91.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. https://app.cochat.ai/papers/10.1136/annrheumdis-2015-208840
The paper
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E., Chambers, C., da Silva, J., Nelson-Piercy, C., Cetin, I., Costedoat-Chalumeau, N., Dolhain, R., Förger, F., Khamashta, M., Ruiz-Irastorza, G., Zink, A., Vencovsky, J., Cutolo, M., Caeyers, N., Zumbühl, C., & Østensen, M. (2016). The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2015-208840

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.